Psychiatry
Partner With Us
Advertisement
Conexiant chevron_right Psychiatry chevron_right FDA Clears Esketamine Monotherapy for Depression
FDA & Government News

FDA Clears Esketamine Monotherapy for Depression

"[Esketamine] is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days—without the need for daily oral antidepressants."

Conexiant
article Full Article subject Summary summarize Notecard
  1. Esketamine nasal spray was approved as first monotherapy for treatment-resistant depression.
  2. 22.5% of patients treated with the agent achieved remission at week 4.
  3. Safety profile was consistent with real-world data.  
  4. Target neurotransmitter: glutamate.
  5. Administered to more than 140,000 patients worldwide.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.